US health agency questions robustness of AstraZeneca's Covid-19 vaccine trial data

AstraZeneca Plc may have provided an incomplete view of efficacy data on its Covid-19 vaccine from a large-scale US trial, a US health agency said Tuesday in a fresh setback for the shot.

The news comes just one day after interim data from the drugmaker showed better-than-expected results from the trial and casts doubt on its plan to seek US emergency use authorisation for the vaccine in the coming weeks...